Treadwell-Announces-Initiation-Phase-2-Study-CFI-400945

Aug 12, 2020

Treadwell Announces Initiation of Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC): IND.239